PHILADELPHIA (AP) -- Drugmakers are presenting results of new studies of experimental diabetes treatments offering patients hope of better controlling blood sugar and weight and preventing dangerously low blood sugar. Those are all big challenges for millions of diabetics.
Results from key studies of several new diabetes drugs and insulin products are being announced at the American Diabetes Association conference in Philadelphia.
They include Novo Nordisk's degludec, an ultra-long-acting insulin for Type 2 diabetes that doesn't need to be taken at the same time each day and prevents low blood sugar during the night better than market-leading Lantus.
Johnson & Johnson presented studies on its daily Type 2 diabetes pill, canagliflozin, part of a new drug class.
To comment, the following rules must be followed:
Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.
Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Questions may be sent to firstname.lastname@example.org.
Please provide detailed information.
All comments must adhere to the WSAW.com discussion rules.